HeidelbergCapital is an independent Private Equity Funds Group, specialising in Secondary Direct Investments, e.g. the acquisition of shareholdings in companies previously held by private equity/venture capital funds or banks.

News

31.01.2018


4SC:
Positive DSMB safety review of 4SC’s pivotal RESMAIN study of resminostat in CTCL

25.01.2018


Nanogate
SE Expects 2018 Operating Result (EBITDA) of More Than EUR 24 Million and Sales of at Least EUR 220 Million

22.01.2018


4SC
AG strengthens patent protection for its Hedgehog/GLI signaling inhibitor 4SC-208

10.01.2018


Nanogate
SE: Market Launch of New Technology Platform to Replace Stainless Steel

20.12.2017


4SC
receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency

11.12.2017


4SC
receives milestone payment from Immunic

About us


HeidelbergCapital was founded mid 2007. The company is jointly managed by Dr. Clemens Doppler and Prof. Dr. Martin Weiblen, former Managing Director of a multi-billion family office in London/U.K. and advisor to several Life Science-Funds. Dr. Clemens Doppler is a former Partner at 3i, the British Private Equity Group. The New York based Private Equity Investor Auda has committed c150m USD for the first fund, HeidelbergCapital Private Equity Fund I.

The portfolio of HeidelbergCapital ranges from investments in later stage venture companies with a proven business model to established mid-size operations. As an active partner, HeidelbergCapital supports the companies in strategic business decisions, but also provides, where appropriate, funding for further growth.

Investments

4sc – Martinsried (D)

Drug development company

MerLion – Singapur

Drug development company

Nanogate – Saarbrücken (D)

High performance surfaces

Vasopharm – Würzburg (D)

Drug development company

Wirelane – Saarbrücken (D)

Mobility services